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Introduction 
Neuromuscular diorders can be divided into 1) myopathies, primary disease of the 
muscle fiber, 2) myasthenias, diseases caused by defects of the neuromuscular junction and 3) 
neurogenic muscular atrophies, caused by the defects of the motor nerve. Muscular 
dystrophies are a heterogeneous group of myopathies. They are genetic disorders caused by 
muscle fiber degeneration often causing progressive weakness and wasting and they can be 
further divided into the following 
Myotonic dystrophies – DM1 andDM2 
Dystrophinopathies - DMD, BMD 
Facioscapulohumeral - FSHD 
Limb-girdle – LGMD subtypes 
Distal muscular dystrophies 
Congenital dystrophies - CMD 
Oculofaryngeal - OPM, OPDM 
Emery-Dreifuss - X-EMD, AD-EMD 
Other and unclassified muscular dystrophies 
Myotonic dystrophy (Dystrophia myotonica, DM) is the most common inherited 
muscular dystrophy in adults. Two different types of myotonic dystrophy have been 
identified. Both myotonic dystrophy type 1 (DM1, Steinert´s disease [OMIM #160900]) and 
type 2 (DM2, [OMIM #602668]) are dominantly inherited disorders caused by repeat 
expansion mutations. The estimated prevalence of DM1 is 1/8000 (Harper 2001), while in 
DM2 the prevalence has not been established, but is considered to be even as common as 
DM1 in many European populations (Udd 2006). 
DM1 was described one hundred years ago and the (CTG)n trinucleotide repeat expansion 
mutation in the 3´untranslated region (UTR) of the DMPK gene was identified in 1992. The 
gene is located in chromosome 19q13.3 (Brook; Fu; Mahadevan 1992). The mutation 
underlying DM2 disease is a (CCTG)n tetranucleotide expansion located in the first intron of 
ZNF9 gene on chromosome 3q21 (Liquori 2001). The repeat expansion size in DM1 may vary 
from more than 50 to more than 3000 repeats and there is a gross correlation between repeat 
length and disease severity. The number of repeats in the expansion mutation causing DM2 
varies from 75 to 11000. No correlation in the disease severity and the size of the expansion 
mutation has been shown in DM2. There is no clear evidence for anticipation in DM2 as there 
is in DM1, in which successive generations inherit increasing disease severity with decreasing 
age of onset due to increased size of the repeat expansion (Day 2003). In both DM1 and DM2 
the molecular pathomechanism is based on RNA gain-of-function. Transcription of the 
repeats into mutant (CUG)DM1/(CCUG)DM2-containing RNAs is both necessary and sufficient 
to cause disease by formation of ribonuclear foci and interference of the splicing of 
downstream “effector” genes through trans-acting splicing factors, namely muscleblind 1 
(MBLN1) (Osborne 2006, Ho 2005) and CUG binding protein 1 (CUGBP1) (Timchenko 
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2006) . Several ‘effector’ genes including, CLCN1 (chloride channel-1), INSR (insulin 
receptor), TNNT2 (cardiac troponin T), TNNT3 (skeletal fast troponin T), ZASP, ATP2A1 
(SERCA1) and MAPT (microtubule-associated protein tau) show aberrant splicing in DM1, 
and in DM2. (Charlet-B N 2002, Mankodi 2002, Maurage 2005, Savkur 2004) 
 
DM1 and DM2 mutations 
The DM1 mutation was identified in 1992 as an expanded trinucleotide (CTG)n repeat 
track in the 3´ untranslated (UTR) region of the dystrophia myotonica protein kinase coding 
gene (DMPK; OMIM *605377) (Brook; Fu; Mahadevan 1992)In DM1 patients the repeat 
sizes range from 50 – 4000 (150 – 12,000 bp), whereas normal individuals have 5 – 37 
repeats. Repeat lengths 38 – 49 are considered a premutation allele pool, showing decreased 
stability. The DM1 mutation length predicts the clinical outcome so some extent: classical 
DM1 100 – 1,000 repeats; congenital >2,000 repeats. 
The mutation causing DM2 was identified in 2001 in the first intron of the zinc finger 
9 (ZNF9) protein coding gene CNBP (ZNF9; OMIM *116955) (Liquori 2001). This means 
that both DM1 and DM2 mutations consist of long uninterrupted repeat tracks, which are 
thermodynamically less stable than the normal alleles, which show a more complex pattern 
with interrupting sequences.  
 
Symptoms 
Both DM1 and DM2 are progressive multisystemic disorders with both shared and 
distinct clinical features and pathomechanisms. The core symptoms expressed at various 
degrees in DM2 include proximal muscle weakness, muscle pain, myotonia, posterior 
subcapsular iridescent cataracts, tremors, cardiac conduction defects, and endocrinological 
disturbances such as increased insulin resistance and male hypogonadism.Laboratory findings 
include elevated creatine kinmase (CK), hypo IgG, positive autoimmune serology (Tieleman 
2009) and elevated liver enzyme γ-glutamyl transferase (Udd 2003, Day 2003). Many of the 
clinicamanifestations are similar in classical adult onset DM1, although with also clearly 
distinct features: more severe weakness of distal and facial muscles, including ptosis leading 
to  dysphagia and respiratory deficiency. The congenital DM1 form and the early childhood 
onset form with mental retardation in DM1 are not observed in DM2 (Harper 2001, Turner 
2010). 
 
Muscle histopathology in myotonic dystrophies 
Muscle histopathology in DM1 and DM2 share some general common chronic 
myopathic features, such as high number of central nuclei and fiber size variation which were 
initially reported to be quite similar (Ricker 1994, Thornton 1994). The muscle pathology is 
progressive, with end-stage pathology showing severe reduction in fiber number and size 
accompanied with fatty and connective tissue replacement in the most severely affected 
muscles (Harper 2001). In DM1, ring fibers and sarcoplasmic masses are more frequent, and 
type 1 fibers are generally more affected (Harper 2001).  
In general, muscle wasting in DM2 is less prominent, and in accordance with this, 
severe muscle fiber loss is not usually encountered. The biopsies show usually mild to 
moderate myopathic changes, and more severe fatty replacement and fibrosis, typically 
starting in the interfascicular space, is observed only in proximal muscles of older patients 
with considerable muscle weakness. The number of internalized nuclei is greater in type 2 
fibers in DM2, and in type 1 fibers in DM1, further reinforcing the observation that the 
distinct fiber populations are differentially affected in DM1 and DM2 (Bassez 2008, Pisani 
2008). Fiber atrophy is seen in most biopsies; small angulated fibers and atrophic nuclear 
clump fibers, similar to those in neurogenic atrophy, are a frequent finding, (Day 2003, Vihola 
2003, Schoser 2004), whereas small group atrophy is less common and fiber type grouping is 
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not observed (Vihola 2003, Schoser 2004). In addition, there is a number of rather infrequent 
findings in DM2 muscle, including occasional moth-eaten fibers, rimmed vacuolar and 
ragged-red fibers (Vihola 2003, Schoser 2004). Necrotic fibers, ring fibers, targetoid fibers, 
and subsarcolemmal or sarcoplasmic masses are rarely seen in DM2. 
 However, it was only after using the immunohistochemical method for fiber type 
differentiation in the muscle sections, that the preferential fiber type 2 atrophy was fully 
recognized in DM2 (Vihola 2003), even though the possibility of it had been suggested 
previously (Bassez,G. 2001). Schoser et al. later confirmed the finding with a larger set of 
samples (Schoser 2004). It should be noted, that there is hypertrophy of both fiber types in 
DM2 (Vihola 2003), and also atrophy of type 1 fibers occurs in DM2, however, to lesser 
extent: percentage of atrophic type 1 fibers is lower than that of type 2 fibers (Vihola 2003, 
Schoser 2004), and practically all very atrophic  fibers (< 5um) are of type 2 in DM2; whereas 
in DM1, the very atrophic fibers occur later in muscle histopathology, together with other 
signs of advanced pathology, and typically express both fast and slow myosin isoforms. 
No clear correlation has been observed between the pattern of muscle 
histopathological findings and the clinical muscle phenotype, regarding myotonia, cramps, 
weakness and myalgia, or the order of onset of symptoms (Schoser 2004). Internalized nuclei 
and scattered nuclear clump fibers may be prominent even in clinically asymptomatic muscle. 
 
Pathomechanisms in myotonic dystrophies 
The main molecular pathomechanism underlying the myotonic dystrophies is 
dominant RNA gain-of-function (Mankodi 2000, Liquori 2001, Lee 2009). The expansion 
mutation, (CCTG)n in DM2 and (CTG)n in DM1, is transcribed but not translated, and the 
mutant RNA itself is necessary and sufficient to induce the molecular events leading to 
clinical symptoms. The mutant repeat RNA species are retained in the nucleus, where they 
aggregate and sequester RNA-binding proteins, forming the ribonuclear inclusions typical of 
DM1 and DM2 (Taneja 1995, Liquori 2001). According to the present knowledge, the mutant 
RNA exerts its toxic effect via disturbing the distribution and function, and hence the 
equilibrium between the two antagonistic splicing factors, MBNL1 (muscleblind-like 1) and 
CUGBP1 (CUG-binding protein 1), resulting in aberrant mRNA splicing, translation, and 
turnover. 
The MBNL and CUGBP1 act as antagonist splicing regulators, often/sometimes  
promoting opposite splicing events in their mutual target genes, and their binding sites are 
distinct (Ho 2004). Both of them regulate multiple alternative splicing events. The important 
downstream effect of the dysregulation of these two antagonistic splicing factors is the 
aberrant splicing in myotonic dystrophies, resulting in inappropriate embryonic splicing 
pattern, which is considered the main cause of direct symptoms. More than 20? aberrant 
splicing events have been identified in DMs, summarized in table x. Of these, at least CLC1 
has been linked to myotonia (Charlet-B 2002, Mankodi 2002, Wheeler 2007); insulin receptor 
(IR) to insulin resistance (Savkur 2001); and cTNT (cardiac troponin T) to cardiac problems 
(Philips 1998). 
 
The atrophy of type 2 fibers in DM2 
In this thesis work the concept of very atrophic fibers is used referring to the pool of 
very small fibers with a diameter < 6 µm. They are characteristic for DM2 where they appear 
very early in the disease course, even in  clinically unaffected muscles. Morphologically, they 
fall into at least three categories: (1) nuclear clump fibers, (2) extremely small fibers (< 6 µm) 
with very little cytoplasm and none to few nuclei (in the plane of sectioning), and (3) very 
thin, angulated fibers.  Most of these fibers are round and scattered. They seem to represent a 
unique pool of fibers, because they form a distinct population apart from larger type 2A fibers. 
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They may be encountered in DM1, but only in later stages of pathology, less numerous 
compared to DM2 and in DM1 they may also express slow MyHC. 
It is not clear if (1) and (2) represent distinct fiber populations. Examination of 
longitudinal sections suggests that they may represent a single population of fibers, which 
show differential morphology depending on the number of nuclei trapped inside the slim 
fibers at the section site. 
The nuclear clump fibers in DM2 are morphologically indistinguishable from those 
seen in neurogenic atrophy, where they form as an end product of denervation atrophy in the 
absence of re-innervation. However, no primary neurogenic involvement has been shown in 
myotonic dystrophies, which is supported by the lack of fiber type grouping. 
 
Protein expression in very atrophic fibers 
We carried out further studies on protein expression in DM2 and DM1 muscles to 
identify possible differences between them, which could lead to better understanding of their 
differential muscle and fiber type involvement. In addition, due to the presence of nuclear 
clump fibers in myotonic dystrophies, similar to neurogenic atrophy, we also included a group 
of patients with various neurogenic disorders.  
Altogether, we characterized the expression of 14 proteins, which are involved in 
muscle contraction and Ca2+ handling, regeneration, denervation, and apoptosis, by 
immunohistochemistry. A subset of the proteins show preferential expression in type 2 fibers 
as described below. Myosin heavy chain (MyHC)-encoding genes (MYH1,2, -3, -7 and -8) are 
differentially regulated in fast and slow fibers, and during muscle development.  The 
expression of MyHC-IIa isoforms in the highly atrophic fibers of DM2 was confirmed with 
three different monoclonal antibodies raised against fast type myosin heavy chains. As a new 
finding, we showed that the population of very small fibers in DM1 co-expressed myosins fast 
IIa and beta/slow, in contrast to DM2, where they expressed only type IIa. In neurogenic 
atrophies, virtually all small atrophic fibers expressed MyHC-IIa, showing moderate to high 
co-expression of MyHC-beta/slow. The MyHC-pn is widely used as a regeneration marker 
(Dubowitz 2007). There was high expression of the  MyHC-pn isoform in very atrophic fibers 
in all groups. Since the majority of very atrophic fibers in progressive neurogenic atrophy 
without any regeneration activity express MyHC-pn, this may be turned on and expressed also 
by other mechanisms than regeneration.  MyHC-emb positive fibers were absent in most 
biopsies, showing expression in a few DM fibers only in the biopsies with advanced muscle 
pathology.This observation is congruent with its reported expression mostly in small 
basophilic regenerating fibers having survived severe injury such as withmuscular dystrophies 
and other necrotic myopathies (Dubowitz 2007). A similar finding was observed with the 
transcription factor myogenin (MYOG), and the intermediate filament protein vimentin (VIM), 
which appear early during myogenesis and serve as regeneration markers in muscular 
dystrophies (Dubowitz 2007, Olive 1997). 
Neural cell adhesion molecule (NCAM-1) has distinct roles in myogenesis, 
synaptogenesis, and synaptic maintenance (Covault 1986). It is transiently re-expressed after 
denervation and during re-innervation, decreasing progressively as regeneration proceeds 
(Winter 1999). Hence, it has been  a candidate marker for recently occurred denervation 
atrophy. Interestingly, we found that one third of the atrophic fibers in DM2 abundantly 
expressed NCAM-1, outnumbering the small fibers in DM1, and even more intriquingly, the 
severely atrophic fibers in neurogenic atrophies. In fact, the pattern of NCAM-1 expression 
was different in the latter group, showing positive signal more frequently in intermediate-large 
fibers, which was not encountered in any specimens in myotonic dystrophies. The usage of 
NCAM expression as a marker of neurogenic atrophys thus seems to be very limited. 
Because we were preoccupied with the question why the highly atrophic type 2 fibers 
persist in the DM2 muscle, we investigated the expression of the oncoprotein BCL2 (BCL2) 
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in the muscle biopsies. Apoptosis is required during normal tissue remodeling, development 
and regeneration. BCL2 inhibits cells from entering apoptosis, but it also has a distinct effect 
on cell cycle (Cory 2003). Apoptosis is not generally involved in muscular dystrophies as a 
pathomechanism (Dubowitz 2007). In order to verify this we used an Ab raised against 
activated Caspase-3 (CASP3), a cysteine protease playing a key role in executing apoptosis in 
many cell types, and a commonly used marker for apoptosis (viite). To our surprise, the 
majority of the very atrophic fibers in DM2 expressed BCL2. In contrast, in DM1 BCL2 
immunoreactivity was present in only one biopsy, in which approximately 5% of the very 
small fibers were positive. In neurogenic atrophies, BCL2 positive fibers were moderately 
common, albeit with a lot of dispersion among the samples (range 1-100% positive cells). 
Caspase-3 was not detected in DM2 biopsies, supporting the prevailing concept of apoptosis 
not playing a major role. However, the combined high BCL2 expression and absent Caspase-3 
could offer a partial explanation to the persistence of the very atrophic, non-functional type IIa 
fibers in DM2: the anti-apoptotic BCL2 might prevent the cells from entering apoptosis.  
Another interesting finding in DM2 was revealed when serial sections, stained for MHCpn 
and BCL2, were examined. Mutually exclusive expression of these markers was often 
observed. We do not have a specific explanation to this finding at the moment. 
We observed reduced sarcolemmal labeling of dystrophin and neuronal nitric oxide 
synthase (nNOS) in the very atrophic fibers in DM2. However, these findings, although not 
reported with DM2 before, are likely not specific, as several sarcolemmal proteins are 
reported to show low immunoreactivity in MyH-pn positive, small atrophic fibers (Dubowitz 
2007). We also studied two proteins preferentially expressed in, but not restricted to fast type 
2 fibers: the fast skeletal muscle troponin T (fTnT/TNNT3), a sarcomeric thin filament 
component, and the Ca2+ ATPase SERCA1 (ATP2A1), both of which are involved in 
regulation of muscle contraction (Wu 1994, Brandl 1986). SERCA1 was expressed in 
majority of the atrophic fibers in all groups, whereas fTnT showed moderate to high 
expression in atrophic fibers in DM2 and DM1, and high expression in neurogenic atrophies. 
Unfortunately, even though not strictly following the fast-slow fiber distribution, neither of 
these proteins were differentially expressed in very atophic and regular type 2 fibers, thus 
giving no further insight into the question why a subpopulation of type IIa fibers are subject to 
severe atrophy in DM2. 
It should be noted that the neurogenic atrophies was the most heterogeneous group, 
relative to MyHC-pn, NCAM-1 and BCL2 expression in the very small, atrophic fibers, 
showing more dispersion in results and greater standard deviation values. This is 
understandable because of their divergent etiologies. 
 
Satellite cells 
Defective myoblast-myotube differentiation in cultures from satellite cells have been 
reported with DM1. Similar findings have not been observed in DM2. However, repeatedly in 
our DM2 cell cultures myoblast proliferation after 4-5 passages has been limited even if 
differentiation seemed to be normal. 
Pax7 is expressed in quiescent skeletal muscle satellite cells, and considered an 
appropriate protein marker (Relaix 2005). The number of satellite cells has been reported to 
decline with age (Sajko 2004). As a separate experiment, we assessed the number of skeletal 
muscle satellite cells in DM2 (n=4), DM1 (n=5), neurogenic atrophy (n=4), and healthy 
control (n=1), approximately 200 fibers were included per biopsy, counting all fibers in 
randomly selected fields. The number of Pax7 positive cells in satellite cell position was 
proportioned to the total number of fibers; the results are indicated as the number of Pax7+ 
cells (in satellite cell position) per 100 muscle fibers counted: 
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DM2 DM1 NA C 
25 20 20 7 
NA, neurogenic atrophy; C, healthy control 
 
  There were other Pax7+ cells present in the interstitial space of the biopsies examined, 
which likely represent a distinct pool of progenitor cells and these were not included in the 
numbers of satellite cells. The results indicate that the number of spindle-shaped, Pax7+ 
positive cells in satellite cell position was increased in all diases groups, compared to control 
biopsy. We observed the highest number of Pax7+ cells in DM2. The reported proportion of 
satellite cells in human muscle normally varies between 3-6% of all muscle fiber nuclei 
(Sajko 2004), which is in accordance with our control muscle. The number of satellite cells is 
affected by age and muscle type. The increase of satellite cells in DM2, DM1 and neurogenic 
atrophy is probably caused by basic attempts to regenerate in response to muscle injury. The 
results are congruent with previous reports of DM2 and DM1 indicating unaffected satellite 
cell proliferation (Furling 2001, Pelletier 2009). 
 
Conclusion 
Defective control of gene expression which leads to abnormalities in a large number of 
proteins expressed in the muscle fibers is one component of the molecular pathology 
underlying the myotonic dystrophies. To a major extent these abnormalities are based on 
abnormal splicing events due to malfunction of MBLN1. According to the global impact of 
the primary mutations on RNA-metabolism also other machineries in the muscle cell such as 
translation and turnover handling are affected. Considering these large scale molecular 
changes, any therapy towards a limited sector of abnormal gene and protein expression may 
not be very successful, and approaches to directly eliminate the mutant transcripts generated 
by the primary repeat expansion mutations should be the target in the search for curative 
treatment. 
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